股本结构
单位：万股
| 公告日期 | 2026-08-14 | 2026-07-23 | 2026-08-14 | 2026-07-20 | 2026-05-15 | 2026-05-15 |
|---|---|---|---|---|---|---|
| 证券总股本 | 1693.07 | 301.73 | 101.16 | 105.85 | 95.03 | 91.70 |
| 普通股本 | 1693.07 | 301.73 | 101.16 | 105.85 | 95.03 | 91.70 |
| 优先股 | 未披露 | 未披露 | 121.57 | 未披露 | 未披露 | 121.56 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-08-10 | 2026-07-23 | 2026-06-30 | 2026-06-20 | 2026-05-12 | 2026-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-08-14 | 1693.07 | 未披露 | 定期报告 | 2026-08-10 |
| 2026-07-23 | 301.73 | 未披露 | 定期报告 | 2026-07-23 |
| 2026-08-14 | 101.16 | 121.57 |
更多>>
From March 31, 2026 to June 30, 2026
Payment of SEPA commitment fee in common shares
Conversion of convertible note into common stock
|
2026-06-30 |
| 2026-07-20 | 105.85 | 未披露 | 定期报告 | 2026-06-20 |
| 2026-05-15 | 95.03 | 未披露 | 定期报告 | 2026-05-12 |
| 2026-05-15 | 91.70 | 121.56 |
更多>>
From December 31, 2025 to March 31, 2026
Issuance of Series C Preferred Stock, net of issuance costs
|
2026-03-31 |
| 2026-04-15 | 91.70 | 0.14 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of Series A Preferred Stock in connection with the acquisition of Polynoma, net of issuance costs
Proceeds from issuance of Series B preferred stock, net of issuance costs
Transaction costs paid through the issuance of Series A Preferred Stock
Issuance of common stock, net of offering costs
|
2025-12-31 |
| 2025-11-14 | 91.70 | 未披露 | 定期报告 | 2025-11-10 |
| 2025-11-14 | 83.37 | 未披露 | 定期报告 | 2025-09-30 |
| 2025-08-14 | 83.37 | 未披露 | 定期报告 | 2025-06-30 |
| 2025-05-05 | 83.36 | 未披露 |
更多>>
1-for-28 reverse stock split
|
2025-05-15 |
| 2025-03-25 | 2334.13 | 未披露 |
更多>>
Common stock offered 10,250,000 shares by the company
|
2025-03-25 |
| 2025-03-25 | 1309.13 | 未披露 | 定期报告 | 2025-03-21 |
| 2025-04-15 | 102.91 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuances of common stock, net
|
2024-12-31 |
| 2024-12-06 | 69.62 | 未披露 |
更多>>
1-for-33 reverse stock split
|
2024-12-04 |
| 2024-11-14 | 1726.57 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Issuances of common stock, net
|
2024-09-30 |
| 2024-07-24 | 1726.57 | 未披露 |
更多>>
Common stock offered 10,000,000 shares by the company
|
2024-07-24 |
| 2024-08-14 | 726.57 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Issuances of common stock, net
|
2024-06-30 |
| 2024-06-21 | 726.57 | 未披露 | 定期报告 | 2024-06-21 |
| 2024-05-15 | 662.21 | 未披露 | 定期报告 | 2024-05-10 |
| 2024-04-29 | 610.81 | 未披露 | 定期报告 | 2024-04-22 |
| 2024-05-15 | 580.81 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Issuances of common stock, net
|
2024-03-31 |
| 2024-04-01 | 580.81 | 未披露 | 定期报告 | 2024-03-20 |
| 2024-01-22 | 105.64 | 未披露 |
更多>>
Common stock offered 428,924 shares by the company
|
2024-01-22 |
| 2024-01-11 | 62.74 | 未披露 |
更多>>
TransCode Therapeutics, Inc. announced that its Board of Directors has approved a 1-for-40 reverse stock split, to be effective at 12:01 a.m. Eastern Standard Time Tuesday, January 16, 2024.
|
2024-01-16 |
| 2023-12-01 | 2509.76 | 未披露 |
更多>>
Common Stock offered 5,000,000 shares by the company
|
2023-12-04 |
| 2023-10-26 | 2009.76 | 未披露 | 定期报告 | 2023-10-25 |
| 2023-11-14 | 1068.77 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuances of common stock, net
|
2023-09-30 |
| 2023-09-27 | 360.07 | 未披露 |
更多>>
Common Stock offered 700,000 shares by the company
|
2023-09-28 |
| 2023-09-25 | 290.07 | 未披露 | 定期报告 | 2023-09-21 |
| 2023-08-14 | 202.57 | 未披露 | 定期报告 | 2023-08-04 |
| 2023-08-14 | 195.07 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuances of common stock, net
|
2023-06-30 |
| 2023-06-07 | 284.99 | 未披露 |
更多>>
Common Stock offered by the company 2,000,000 shares
|
2023-06-09 |
| 2023-05-22 | 84.99 | 未披露 |
更多>>
a 1 for 20 split of it's common stock
|
2023-05-23 |
| 2023-05-15 | 1699.85 | 未披露 | 定期报告 | 2023-05-11 |
| 2023-05-15 | 1582.35 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuances of common stock, net
|
2023-03-31 |
| 2023-02-17 | 1582.35 | 未披露 |
更多>>
Common Stock offered 2,846,300 shares by the company
|
2023-02-17 |
| 2022-05-02 | 1297.72 | 未披露 | 定期报告 | 2022-04-29 |
| 2021-11-15 | 1290.46 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock in initial public offering, net of offering costs
Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering
Exercise of warrants
|
2021-09-30 |
| 2021-08-23 | 1290.46 | 未披露 | 定期报告 | 2021-08-20 |
| 2021-07-09 | 1196.71 | 未披露 |
更多>>
1.Common Stock offered by company 6,250,000 shares
2.The number of shares of common stock to be outstanding after the offering is based on 5,717,074 shares of common stock outstanding as of March 31, 2021
|
2021-07-09 |
| 2021-08-23 | 463.62 | 未披露 | 定期报告 | 2021-06-30 |
| 2021-05-03 | 1195.73 | 未披露 | 定期报告 | 2021-05-14 |
From March 31, 2026 to June 30, 2026
Payment of SEPA commitment fee in common shares
Conversion of convertible note into common stock
From December 31, 2025 to March 31, 2026
Issuance of Series C Preferred Stock, net of issuance costs
From December 31, 2024 to December 31, 2025
Issuance of Series A Preferred Stock in connection with the acquisition of Polynoma, net of issuance costs
Proceeds from issuance of Series B preferred stock, net of issuance costs
Transaction costs paid through the issuance of Series A Preferred Stock
Issuance of common stock, net of offering costs
1-for-28 reverse stock split
Common stock offered 10,250,000 shares by the company
From December 31, 2023 to December 31, 2024
Issuances of common stock, net
1-for-33 reverse stock split
From June 30, 2024 to September 30, 2024
Issuances of common stock, net
Common stock offered 10,000,000 shares by the company
From March 31, 2024 to June 30, 2024
Issuances of common stock, net
From December 31, 2023 to March 31, 2024
Issuances of common stock, net
Common stock offered 428,924 shares by the company
TransCode Therapeutics, Inc. announced that its Board of Directors has approved a 1-for-40 reverse stock split, to be effective at 12:01 a.m. Eastern Standard Time Tuesday, January 16, 2024.
Common Stock offered 5,000,000 shares by the company
From June 30, 2023 to September 30, 2023
Issuances of common stock, net
Common Stock offered 700,000 shares by the company
From March 31, 2023 to June 30, 2023
Issuances of common stock, net
Common Stock offered by the company 2,000,000 shares
a 1 for 20 split of it's common stock
From December 31, 2022 to March 31, 2023
Issuances of common stock, net
Common Stock offered 2,846,300 shares by the company
From June 30, 2021 to September 30, 2021
Issuance of common stock in initial public offering, net of offering costs
Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering
Exercise of warrants
1.Common Stock offered by company 6,250,000 shares
2.The number of shares of common stock to be outstanding after the offering is based on 5,717,074 shares of common stock outstanding as of March 31, 2021